The TAIL study determined plasma concentrations of lopinavir/ritonavir (LPV/RTV) over 72 hours following cessation of LPV/RTV (400/100 mg twice daily) in healthy volunteers. There was a rapid decline in LPV concentrations as RTV diminished over time [1] . Here we have determined a model to quantify the changes in LPV apparent oral clearance (CL/F) in relation to RTV concentrations.
Purpose of the study
The TAIL study determined plasma concentrations of lopinavir/ritonavir (LPV/RTV) over 72 hours following cessation of LPV/RTV (400/100 mg twice daily) in healthy volunteers. There was a rapid decline in LPV concentrations as RTV diminished over time [1] . Here we have determined a model to quantify the changes in LPV apparent oral clearance (CL/F) in relation to RTV concentrations.
Methods
Plasma LPV and RTV concentrations were determined by HPLC-MS/MS. Initially, non-linear mixed effects modelling was applied (NONMEM vs. VI) to LPV and RTV data separately using first-order conditional estimation with interaction. Secondly, individual predicted RTV pharmacokinetic (PK) parameters were fed into a model to determine LPV PK parameters assuming competitive inhibition by RTV. Model fit was assessed by statistical and graphical methods. A decrease in minimal objective function value (OFV) of 3.84 points corresponded to a statistically significant difference between hierarchical models.
Summary of results
Sixteen healthy volunteers (six female) were included. A one-compartment model with zero-order absorption was used to generate RTV parameters. Initially, a one-compartment first-order absorption model was used for LPV in the combined model; however, under-prediction of concentrations in the early absorption phase and over-prediction in parts of the elimination phase occurred. A one-compartment zero-order absorption model for LPV improved the fit (OFV -157.934) and was parameterised by LPV clearance in the absence of inhibitor (CL0), apparent volume of distribution (V/F), CL/F and RTV inhibition constant (Ki) with inter-individual variability (IIV) included on CL0 and V/F. Residual error was described by a combined additive-proportional model. A first-pass model produced similar estimations. Parameter estimates and time-dependent changes in LPV CL/F are shown (Table 1 
Conclusion
A model assuming competitive inhibition of LPV by RTV combined with zero-order kinetics best described the time-dependent changes in LPV CL/F following drug cessation. Given the complexity of the LPV-RTV interaction, potentially more complex models should be explored.
